Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03329989 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT03329989: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT03329989 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 158 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03329989, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
An open-label study of safety and effectiveness of EN3835 in the treatment of cellulite in adult women.
Primary Outcome
Percentage of responders defined as participants with an improvement in cellulite severity from baseline of at least 2-levels of severity of at least one buttock (left or right) on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) with ratings ranging from "0" (None) to "4" (Severe). A 2-level responder is a participant with a reduction in severity of at least 2-levels from Baseline at that particular visit. Number of participants analyzed is determined by
Interventions
- BIOLOGICAL Collagenase Clostridium Histolyticum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2017-11-17 |
| Est. Completion | 2018-09-05 |
| Phase | Phase 2 |
What the finished NCT03329989 record still lists
NCT03329989 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher).
The record links to 0 conditions, and to 1 intervention - of which Collagenase Clostridium Histolyticum is the first listed.
NCT03329989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03329989 about?
NCT03329989 is a clinical study titled "Safety and Effectiveness of EN3835 in the Treatment of EFP in Women". An open-label study of safety and effectiveness of EN3835 in the treatment of cellulite in adult women.
What is the current status of trial NCT03329989?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2017-11-17. Estimated completion is 2018-09-05.
What interventions are being tested in trial NCT03329989?
The interventions under investigation include: Collagenase Clostridium Histolyticum (BIOLOGICAL).
Who is sponsoring clinical trial NCT03329989?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03329989's enrollment target sits among peer trials
158 443rd of 2000 higher than 1,558 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI